Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders. / Wenande, Emily; Erlendsson, Andrés Már; Haedersdal, Merete.

I: Seminars in Cutaneous Medicine and Surgery, Bind 36, Nr. 4, 2017, s. 192-201.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Wenande, E, Erlendsson, AM & Haedersdal, M 2017, 'Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders', Seminars in Cutaneous Medicine and Surgery, bind 36, nr. 4, s. 192-201. https://doi.org/10.12788/j.sder.2017.046

APA

Wenande, E., Erlendsson, A. M., & Haedersdal, M. (2017). Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders. Seminars in Cutaneous Medicine and Surgery, 36(4), 192-201. https://doi.org/10.12788/j.sder.2017.046

Vancouver

Wenande E, Erlendsson AM, Haedersdal M. Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders. Seminars in Cutaneous Medicine and Surgery. 2017;36(4):192-201. https://doi.org/10.12788/j.sder.2017.046

Author

Wenande, Emily ; Erlendsson, Andrés Már ; Haedersdal, Merete. / Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders. I: Seminars in Cutaneous Medicine and Surgery. 2017 ; Bind 36, Nr. 4. s. 192-201.

Bibtex

@article{79a315baf99f467994cea96c119caac8,
title = "Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders",
abstract = "Fractional laser-assisted drug delivery (LADD) is increasingly finding its way into clinical practice as a new means to enhance topical drug uptake and improve treatment of cutaneous disorders. To date, LADD has been used for a wide range of conditions, including photodamaged skin, neoplastic lesions, scars, cutaneous infections, and vitiligo as well as for topical anesthetic and aesthetic procedures. Substantiated by randomized controlled clinical trials, strong evidence is available for LADD's usefulness for photodynamic therapy (PDT), for which improved efficacy using laser-assisted photosensitizer treatment is established for actinic keratosis compared with conventional PDT. Over time, the modality has undergone increasing refinement and offers the potential advantages of reduced treatment durations, shortened incubation times, and the replacement of cumbersome, patient-dependent treatment regimens with quick, in-office procedures. Notwithstanding, LADD is still a new enhancement technique, and risks of both local and systemic adverse events are insufficiently explored. With conscientious development, however, LADD promises to improve existing regimens and make new pharmacological treatments a reality for a wide range of cutaneous disorders.",
author = "Emily Wenande and Erlendsson, {Andr{\'e}s M{\'a}r} and Merete Haedersdal",
note = "{\textcopyright}2017 Frontline Medical Communications.",
year = "2017",
doi = "10.12788/j.sder.2017.046",
language = "English",
volume = "36",
pages = "192--201",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B.Saunders Co.",
number = "4",

}

RIS

TY - JOUR

T1 - Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders

AU - Wenande, Emily

AU - Erlendsson, Andrés Már

AU - Haedersdal, Merete

N1 - ©2017 Frontline Medical Communications.

PY - 2017

Y1 - 2017

N2 - Fractional laser-assisted drug delivery (LADD) is increasingly finding its way into clinical practice as a new means to enhance topical drug uptake and improve treatment of cutaneous disorders. To date, LADD has been used for a wide range of conditions, including photodamaged skin, neoplastic lesions, scars, cutaneous infections, and vitiligo as well as for topical anesthetic and aesthetic procedures. Substantiated by randomized controlled clinical trials, strong evidence is available for LADD's usefulness for photodynamic therapy (PDT), for which improved efficacy using laser-assisted photosensitizer treatment is established for actinic keratosis compared with conventional PDT. Over time, the modality has undergone increasing refinement and offers the potential advantages of reduced treatment durations, shortened incubation times, and the replacement of cumbersome, patient-dependent treatment regimens with quick, in-office procedures. Notwithstanding, LADD is still a new enhancement technique, and risks of both local and systemic adverse events are insufficiently explored. With conscientious development, however, LADD promises to improve existing regimens and make new pharmacological treatments a reality for a wide range of cutaneous disorders.

AB - Fractional laser-assisted drug delivery (LADD) is increasingly finding its way into clinical practice as a new means to enhance topical drug uptake and improve treatment of cutaneous disorders. To date, LADD has been used for a wide range of conditions, including photodamaged skin, neoplastic lesions, scars, cutaneous infections, and vitiligo as well as for topical anesthetic and aesthetic procedures. Substantiated by randomized controlled clinical trials, strong evidence is available for LADD's usefulness for photodynamic therapy (PDT), for which improved efficacy using laser-assisted photosensitizer treatment is established for actinic keratosis compared with conventional PDT. Over time, the modality has undergone increasing refinement and offers the potential advantages of reduced treatment durations, shortened incubation times, and the replacement of cumbersome, patient-dependent treatment regimens with quick, in-office procedures. Notwithstanding, LADD is still a new enhancement technique, and risks of both local and systemic adverse events are insufficiently explored. With conscientious development, however, LADD promises to improve existing regimens and make new pharmacological treatments a reality for a wide range of cutaneous disorders.

U2 - 10.12788/j.sder.2017.046

DO - 10.12788/j.sder.2017.046

M3 - Journal article

C2 - 29224037

VL - 36

SP - 192

EP - 201

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 4

ER -

ID: 195045315